Targets › ATP2A2
2 programs from 1 company in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Oct 2027.
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Involved in autophagy in response to starvation. (UniProt, P16615)
Open in Phaseline: the race on ATP2A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sardocor | SRD-001 AAV1-mediated SERCA2a gene therapy for SERCA2a enzyme replacement | ATP2A2 | Phase 1 | DMD-Associated Dilated Cardiomyopathy; Congestive Heart Failure | Oct 2027 |
| Sardocor | AAV1/SERCA2a Adeno-associated virus serotype 1 (AAV1) delivering SERCA2a gene to enhance cardiac calciu | ATP2A2 | Phase 1 | Heart Failure, Diastolic | Aug 2029 |
DMD-Associated Dilated Cardiomyopathy (1) Congestive Heart Failure (1) Heart Failure, Diastolic (1)
protein or peptide (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.